Endocrine Abstracts

bioscientifica Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2020) **70** EP167 | DOI: <u>10.1530/endoabs.70.EP167</u> Diabetes, Obesity, Metabolism and Nutrition

Metabolic disorders and the state of the renin angiotensin—aldosterone system in obese patients with resistant hypertension

Anna Shalimova 1,2 , Valentyna Psarova 3 , Maryna Kochuieva 4 , Olena Kolesnikova 5 & Kostyantyn Prosolenko 6

Author affiliations

¹GI "L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine", Complex Risk Reduction of Chronic non–Communicable Diseases, Kharkiv, Ukraine; ²Kharkiv National Medical University, Internal Medicine No 1, Kharkiv, Ukraine; ³Sumy State University, Sumy, Ukraine; ⁴Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine; ⁵GI "L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine; ⁶Kharkiv National Medical University, Kharkiv, Ukraine

Background: The aim was to establish the features of metabolic disorders and the state of the renin–angiotensin–aldosterone system (RAAS) in obese patients with true and pseudo–resistant arterial hypertension (AH).

Material and Methods: The study included 200 patients with uncontrolled AH and obesity. Patients were initially prescribed dual antihypertensive therapy. Those patients who did not reach target blood pressure (BP) levels after 3 months on dual therapy were additionally assigned a third antihypertensive drug. Of the 98 patients who were assigned triple therapy, 48 patients did not reach target BP (27 patients had pseudo—resistant and 21 patients had true resistant AH). These patients were additionally prescribed a fourth antihypertensive drug (spironolactone). The effectiveness of the treatment was evaluated 6 months after the start of antihypertensive therapy.

Results: After 6 months of therapy, unlike patients without resistance, individuals with resistant AH differed more pronounced metabolic disorders and higher activity of the RAAS. Patients with true resistance differed from pseudo-resistant patients with significantly lower body mass index (BMI); in the absence of differences in BP levels, lipid and carbohydrate profiles, patients with true resistance had significantly higher levels of aldosterone, higher adiponectin levels, and lower leptin level.

Conclusions: Obese patients with true resistance differed from pseudo-resistant patients with significantly lower BMI, higher aldosterone levels, and less pronounced adipokines imbalance.